Hepatocellular Carcinoma cells: activity of Amygdalin and Sorafenib in Targeting AMPK /mTOR and BCL-2 for anti-angiogenesis and apoptosis cell death

Abstract Background Sorafenib (Sor) is the only approved multikinase inhibitor indicated for the treatment of HCC. Previous studies have shown that amygdalin (Amy) possesses anticancer activities against several cancer cell lines; we suggested that these compounds might disrupt AMPK/mTOR and BCL-2....

詳細記述

書誌詳細

主要な著者:	Tarek El-Sewedy, Afrah Fatthi Salama, Amro E. Mohamed, Nashwa M. Elbaioumy, Ali H. El-Far, Aisha Nawaf Albalawi, Alaa Elmetwalli
フォーマット:	Artigo
言語:	Inglês
出版事項:	BMC 2023-09-01
シリーズ:	BMC Complementary Medicine and Therapies
主題:	HCC AMPK /mTOR Angiogenesis Sorafenib Molecular docking Amygdalin
オンライン･アクセス:	https://doi.org/10.1186/s12906-023-04142-1
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!